A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2025-03-06
DOI
https://doi.org/10.1007/s12325-025-03138-2
Citations
1
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis

Kim Papp, Katrin Nopora, Sigrid Balser, Piotr Rewerski et al.
1 citations
Advances in Therapy
Biosimilars and Bioanalytical Methods
0.80
article

A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis

Kim Papp, Katrin Nopora, Sigrid Balser, Piotr Rewerski, Michael Trieb, B Freudensprung
article en
1 citations

Abstract

No abstract available for this paper.
Advances in TherapyVol. 42(5)
University of Toronto (CA), Probity Medical Research (CA), Krakow Cardiovascular Research Institute (PL), Fraunhofer-Gesellschaft (DE)
Good health and well-being
Openalex Percentile: Top 31%
Biosimilars and Bioanalytical Methods
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.